Artiva Biotherapeutics, Inc. (ARTV)
ARTV Stock Price Chart
Explore Artiva Biotherapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ARTV price movements and trends.
ARTV Company Profile
Discover essential business fundamentals and corporate details for Artiva Biotherapeutics, Inc. (ARTV) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jul 2024
Employees
96.00
Website
https://www.artivabio.comCEO
Fred Aslan
Description
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
ARTV Financial Timeline
Browse a chronological timeline of Artiva Biotherapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.64.
Earnings released on 8 May 2026
EPS came in at -$0.95 falling short of the estimated -$0.88 by -7.95%.
Earnings released on 10 Mar 2026
EPS came in at -$0.84 surpassing the estimated -$0.87 by +3.45%.
Earnings released on 12 Nov 2025
EPS came in at -$0.88 surpassing the estimated -$0.92 by +4.35%.
Earnings released on 6 Aug 2025
EPS came in at -$0.87 falling short of the estimated -$0.84 by -3.57%.
Earnings released on 8 May 2025
EPS came in at -$0.83 falling short of the estimated -$0.68 by -22.06%.
Earnings released on 25 Mar 2025
EPS came in at -$0.66 surpassing the estimated -$0.71 by +7.04%.
Earnings released on 12 Nov 2024
EPS came in at -$0.92 falling short of the estimated -$0.68 by -35.29%.
Earnings released on 29 Aug 2024
EPS came in at -$22.00 falling short of the estimated -$4.40 by -400.00%, while revenue for the quarter reached $251.00k .
Earnings released on 30 Jun 2024
EPS came in at -$0.62 .
Earnings released on 31 Dec 2023
EPS came in at -$0.30 , while revenue for the quarter reached $33.49m .
Earnings released on 30 Sept 2023
EPS came in at $1.20 , while revenue for the quarter reached $26.66m .
Earnings released on 30 Jun 2023
EPS came in at -$0.90 .
Earnings released on 31 Mar 2023
EPS came in at -$0.95 , while revenue for the quarter reached $989.00k .
ARTV Stock Performance
Access detailed ARTV performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
